Zacks Research Downgrades USANA Health Sciences (NYSE:USNA) to Strong Sell

USANA Health Sciences (NYSE:USNA) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other research firms have also issued reports on USNA. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Wall Street Zen lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Two investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, USANA Health Sciences has an average rating of “Reduce” and an average price target of $36.00.

USANA Health Sciences Trading Up 2.1%

Shares of USANA Health Sciences stock opened at $19.99 on Wednesday. USANA Health Sciences has a twelve month low of $18.48 and a twelve month high of $38.32. The stock has a market cap of $365.33 million, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 0.86 and a beta of 0.65. The company has a fifty day moving average price of $19.78 and a 200 day moving average price of $25.73.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Thursday, October 9th. The company reported $0.56 EPS for the quarter. USANA Health Sciences had a return on equity of 6.97% and a net margin of 1.86%.The company had revenue of $200.22 million for the quarter. USANA Health Sciences has set its FY 2025 guidance at 1.730-1.730 EPS. Analysts forecast that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director John Turman Fleming sold 1,750 shares of USANA Health Sciences stock in a transaction on Friday, October 31st. The shares were sold at an average price of $19.79, for a total value of $34,632.50. Following the completion of the sale, the director owned 4,565 shares in the company, valued at approximately $90,341.35. The trade was a 27.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frederic J. Winssinger sold 2,000 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $19.21, for a total transaction of $38,420.00. Following the transaction, the director owned 5,986 shares in the company, valued at $114,991.06. This trade represents a 25.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 5,680 shares of company stock valued at $114,090. Insiders own 0.63% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds have recently bought and sold shares of the company. National Bank of Canada FI raised its stake in USANA Health Sciences by 166.6% during the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after buying an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after acquiring an additional 1,901 shares in the last quarter. CWM LLC increased its holdings in shares of USANA Health Sciences by 109.7% in the 2nd quarter. CWM LLC now owns 2,762 shares of the company’s stock valued at $84,000 after acquiring an additional 1,445 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of USANA Health Sciences by 52.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after acquiring an additional 1,327 shares in the last quarter. Finally, Quantbot Technologies LP raised its position in shares of USANA Health Sciences by 19.5% during the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after acquiring an additional 646 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.